Cagrilintide Benefits and Side Effects: A Research Guide

Cagrilintide (development code AM833) is a long-acting synthetic analog of the pancreatic hormone amylin developed by Novo Nordisk. It is engineered for once-weekly subcutaneous administration and is studied both as monotherapy and — most prominently — in fixed-dose combination with semaglutide as CagriSema.

This guide summarises what the published research literature reports about Cagrilintide's mechanism, outcomes investigated, and its side-effect profile. It is written for laboratory researchers and is not medical advice.

Mechanism of Action

Amylin is co-secreted with insulin from pancreatic β-cells and acts at the amylin-receptor complex — a heterodimer of the calcitonin receptor with receptor-activity-modifying proteins (RAMPs 1, 2, 3). Cagrilintide is a non-selective amylin-receptor agonist with extended half-life.

Three principal mechanisms are described:

• Centrally-mediated satiety. Amylin acts on the area postrema and nucleus accumbens to reduce food intake — through a hypothalamic pathway distinct from leptin and GLP-1.
• Delayed gastric emptying. Slows nutrient delivery to the small intestine, prolonging satiety and blunting postprandial glucose excursions.
• Glucagon suppression. Reduces postprandial glucagon, complementing insulin's glucose-lowering effect.

Cagrilintide's long half-life is achieved via a fatty-diacid moiety enabling albumin binding, supporting once-weekly dosing.

Benefits Investigated in Research

Weight Reduction (Monotherapy)

Phase II monotherapy (Lau 2021, Lancet) reported placebo-adjusted weight loss of ~8% at 26 weeks with the 4.5 mg dose — meaningful for a single-mechanism amylin agonist.

Weight Reduction (CagriSema Combination)

The combination of Cagrilintide + Semaglutide (CagriSema) is the headline result in this research literature. Phase II reported ~17% weight loss at 32 weeks with CagriSema 2.4 mg/2.4 mg, and Phase III (REDEFINE-1, 2024) reported ~22.7% at 68 weeks — competitive with tirzepatide. The combination targets two complementary anorectic pathways (amylin satiety + GLP-1 satiety) for additive effect.

Glycemic Control

Modest HbA1c reductions in T2DM cohorts, primarily through suppressed glucagon and delayed gastric emptying.

Cardiometabolic Markers

Reductions in waist circumference, blood pressure and triglycerides reported alongside weight loss.

Side-Effect Profile

The Cagrilintide side-effect profile resembles other GI-active metabolic peptides.

Common (≥10%)

• Nausea, vomiting and diarrhea — dose-dependent and primarily early (titration phase).
• Decreased appetite — expected pharmacology.
• Injection-site reactions — typically mild.

Less Common

• Constipation.
• Dyspepsia.
• Fatigue.

CagriSema-Specific

When combined with semaglutide, GI events are additive but generally remain manageable with slow titration. Discontinuation rates in CagriSema trials are slightly higher than monotherapy semaglutide but lower than would be predicted by simple additivity.

Class Contraindications

• Severe gastroparesis (delayed gastric emptying is a primary mechanism).
• Caution in research models predisposed to hypoglycemia when combined with insulin or insulin secretagogues.

Notably, Cagrilintide does NOT carry the medullary thyroid carcinoma warning of the GLP-1 class.

Dosing in the Published Literature

Phase II monotherapy used weekly subcutaneous doses titrated from 0.16 mg to 4.5 mg over 18 weeks. CagriSema research uses fixed-dose 2.4 mg / 2.4 mg combination once weekly.

Cagrilintide vs Other Metabolic Peptides

| Mechanism | Cagrilintide | Semaglutide | Tirzepatide | | --- | --- | --- | --- | | Amylin-R agonism | ✓ | — | — | | GLP-1R agonism | — | ✓ | ✓ | | GIP-R agonism | — | — | ✓ | | Primary pathway | Area-postrema satiety + slowed gastric emptying | Hypothalamic GLP-1 satiety | Dual incretin |

The amylin pathway is mechanistically distinct from the GLP-1/GIP axis, making combination logical and additive — which is the central research rationale for CagriSema.

Conclusion

Cagrilintide is the only long-acting amylin analog in advanced research. As monotherapy it produces meaningful weight loss; as part of CagriSema it achieves magnitudes competitive with tirzepatide by combining two independent satiety pathways. Its side-effect profile is dominated by GI events that mitigate with slow titration. For research use only.

Research Use Only. This material is provided for laboratory and educational research and is not medical advice. Not for human or veterinary use.